Instil Bio, Inc. (TIL): Nasdaq/NYSE listing notice — Instil Bio receives Nasdaq deficiency notice for bid price below $1.00

Instil Bio, Inc.

Received Nasdaq notice on Jan 24, 2023 for non-compliance with minimum bid price rule (bid < $1 for 30 consecutive days).
Has 180 calendar days until July 24, 2023 to regain compliance by having bid >= $1 for 10 consecutive business days.
May transfer to Nasdaq Capital Market for an additional 180-day compliance period if eligible.
Company intends to monitor bid price and consider options, but no assurance of regaining compliance.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Instil Bio, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1)

Exact text from the filing

January 24, 2023, Instil Bio, Inc. (the “Company”) received a notice from The Nasdaq Stock Market (“Nasdaq”) that the Company is not in compliance with Nasdaq’s Listing Rule 5450(a)(1), as the minimum bid price of the Company’s common stock has been below $1.00 per share for 30 consecutive business days. The notification of noncompliance has no immediate effect on the listing or trading of the Company’s common stock on The Nasdaq Global Select Market. The Company has 180 calendar days, or until July 24, 2023, to regain compliance with the minimum bid price requirement. To regain compliance, th

View on SEC.gov

Browse all listing & compliance notices →

Instil Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001789769-23-000018

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.